Pharmaceutical Sales Techniques & Strategies Flashcards
7 cards from real CNPR practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Pharmaceutical Sales Techniques & Strategies flashcards as text
A physician seems distracted during your detailing visit. What is the most effective response?
Answer: Acknowledge their time constraint and offer a concise 2-minute summary
Adapting to the physician's available time by offering a concise summary shows respect and maximizes the impact of the interaction.
Which closing technique involves summarizing the key benefits agreed upon during the call before asking for commitment?
Answer: Summary close
The summary close recaps the benefits the physician found most compelling, reinforcing value before requesting a prescribing commitment.
What does 'formulary status' most directly affect in a pharmaceutical sales conversation?
Answer: Patient access and out-of-pocket drug costs
Formulary status determines whether a drug is covered by insurance plans, directly impacting patient affordability and likelihood of prescribing.
A rep uses 'reflective listening' during a sales call. What does this technique involve?
Answer: Repeating the physician's concerns back in your own words to confirm understanding
Reflective listening means paraphrasing the physician's statements to demonstrate understanding and build rapport.
When a physician says 'I already have a drug I'm happy with,' this objection is best categorized as:
Answer: Loyalty objection
A loyalty objection reflects satisfaction with a competitor product, requiring the rep to differentiate their drug's unique benefits.
In the context of pharmaceutical sales, what is a 'key opinion leader' (KOL)?
Answer: A physician or researcher whose expertise influences the prescribing behavior of peers
KOLs are respected clinicians or researchers whose opinions and endorsements shape how peers approach treatment decisions.
Which strategy is most effective when launching a new pharmaceutical product in a competitive market?
Answer: Target early adopters and KOLs to build initial advocacy and credibility
Targeting early adopters and KOLs during launch creates influential champions who accelerate broader market acceptance.